These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35604767)

  • 1. Optimal unplanned design modification in adaptive two-stage trials.
    Pilz M; Herrmann C; Rauch G; Kieser M
    Pharm Stat; 2022 Nov; 21(6):1121-1137. PubMed ID: 35604767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.
    Graf AC; Bauer P; Glimm E; Koenig F
    Biom J; 2014 Jul; 56(4):614-30. PubMed ID: 24753160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of adaptive designs with respect to a performance score.
    Herrmann C; Kieser M; Rauch G; Pilz M
    Biom J; 2022 Aug; 64(6):989-1006. PubMed ID: 35426460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials.
    Kunzmann K; Grayling MJ; Lee KM; Robertson DS; Rufibach K; Wason JMS
    Stat Med; 2022 Feb; 41(5):877-890. PubMed ID: 35023184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Power Derivative Principle, and Its Application to How and When to Perform a One-Shot Unblinded Reassessment Sample Size.
    Blondiaux E; Derobert E
    Ther Innov Regul Sci; 2020 Jan; 54(1):117-127. PubMed ID: 32008247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized adaptive enrichment designs for three-arm trials: learning which subpopulations benefit from different treatments.
    Steingrimsson JA; Betz J; Qian T; Rosenblum M
    Biostatistics; 2021 Apr; 22(2):283-297. PubMed ID: 31420983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A variational approach to optimal two-stage designs.
    Pilz M; Kunzmann K; Herrmann C; Rauch G; Kieser M
    Stat Med; 2019 Sep; 38(21):4159-4171. PubMed ID: 31264243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal planning of adaptive two-stage designs.
    Pilz M; Kunzmann K; Herrmann C; Rauch G; Kieser M
    Stat Med; 2021 Jun; 40(13):3196-3213. PubMed ID: 33738842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
    Żebrowska M; Posch M; Magirr D
    Stat Med; 2016 May; 35(12):1972-84. PubMed ID: 26694878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving sample size recalculation in adaptive clinical trials by resampling.
    Herrmann C; Kluge C; Pilz M; Kieser M; Rauch G
    Pharm Stat; 2021 Nov; 20(6):1035-1050. PubMed ID: 33792167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stepwise two-stage sample size adaptation.
    Wan H; Ellenberg SS; Anderson KM
    Stat Med; 2015 Jan; 34(1):27-38. PubMed ID: 25252082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive sample size modification in clinical trials: start small then ask for more?
    Jennison C; Turnbull BW
    Stat Med; 2015 Dec; 34(29):3793-810. PubMed ID: 26172385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation.
    Herrmann C; Pilz M; Kieser M; Rauch G
    Stat Med; 2020 Jul; 39(15):2067-2100. PubMed ID: 32249968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.